Wednesday, June 24, 2009
WEDNESDAY, June 24 (HealthDay News) -- Biomarkers of vascular normalization may be helpful in predicting the response of glioblastoma patients to cediranib treatment, according to research published online June 23 in Cancer Research.
A. Gregory Sorensen, M.D., of the Massachusetts General Hospital in Boston, and colleagues analyzed data from 31 patients with recurrent glioblastoma treated with cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases. The researchers assessed vascular parameters before and after cediranib treatment using advanced MRI and blood testing.
The researchers found that changes in Ktrans, a marker of vessel permeability, microvessel volume, and circulating collagen IV after a day of therapy were associated with duration of overall survival or progression-free survival. A vascular normalization index that combined these factors was associated with overall survival and progression-free survival.
"The ability to identify tumor-specific changes rapidly after treatment may allow tailoring of therapy to those patients most likely to benefit, and early discontinuation of an ineffective therapy in others. In addition, these biomarkers could also be valuable for treatment of benign tumors (e.g., schwannomas) or non-neoplastic diseases (e.g., macular degeneration) characterized by abnormal vessels. The biomarker candidates from this hypothesis-generating study need to be validated in large trials as predictive biomarkers and methodology needs to be established for its clinical use in individual glioblastoma patients," the authors write.
Several co-authors reported relationships with a variety of relevant companies.
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.